Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



GEN Poll

More »
Nov 18, 2011

Joint Infringement

Do you think the en banc arguments will change the standing infringement decisions for the Akamai and McKesson cases?

Yes
 
  42.9%
No
 
  42.9%
Undecided
 
  14.3%

Suggest a Poll
More Polls » View Results »

En banc oral arguments about a pair of Federal Circuit cases are being closely watched by the biopharma industry. Stakeholders are seeking clearer direction on when patents can be considered jointly infringed. Earlier this year, separate Federal Circuit panels held there was no viable legal theory to support findings that defendants in the two cases engaged in joint infringement, despite a contractual relationship in Akamai Technologies, Inc. v. Limelight Networks, Inc. and a doctor/patient relationship in McKesson Technologies Inc. v. Epic System Corp. More information can be found here. BIO, PhRMA, and Myriad Genetics support the plaintiffs, Akamai and McKesson, and assert that current stipulations of joint infringement could be detrimental to personalized medicine.

GEN Poll

More » Poll Results » Archive »

GEN’s Hall of Shame

Will you be voting for any of the candidates on GEN’s Hall of Shame list in the next election?

Suggest a Poll